A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management-Reference-Cited by-同舟云学术

A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management

Published:2018-03-07 Issue:431 Volume:10 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Sun Xilin¹²³^ORCID,Xiao Zunyu¹,Chen Gongyan⁴,Han Zhaoguo¹,Liu Yang¹,Zhang Chongqing¹,Sun Yingying²,Song Yan¹,Wang Kai¹²,Fang Fang²,Wang Xiance¹,Lin Yanhong¹,Xu Lili⁵,Shao Liming⁵,Li Jin⁶^ORCID,Cheng Zhen³^ORCID,Gambhir Sanjiv Sam³^ORCID,Shen Baozhong¹²^ORCID

Affiliation:

1. Molecular Imaging Research Center, Harbin Medical University (MIRC), Harbin, Heilongjiang 150028, China.

2. TOF-PET/CT/MR Center, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang 150028, China.

3. Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA.

4. Department of Respiratory Medical Oncology, The Tumor Hospital Affiliated Harbin Medical University, Harbin, Heilongjiang 150049, China.

5. School of Pharmacy, Fudan University, Shanghai 201203, China.

6. College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150081, China.

Abstract

18 F-MPG PET/CT enables noninvasive identification of NSCLC patients who may benefit from EGFR-TKI therapy and can be used to monitor treatment outcome.

Funder

National Natural Science Foundation of China

National Basic Research Program of China

Heilongjiang Province Foundation for Returned Overseas Chinese Scholars

Key Laboratory of Molecular Imaging Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference36 articles.

1. “Precision Medicine” Lister Hill National Center for Biomedical Communications U.S. National Library of Medicine National Institutes of Health Department of Health & Human Services published online 1 December 2016; https://ghr.nlm.nih.gov/primer/precisionmedicine/definition.

2. Moving toward precision medicine

3. Non–Small Cell Lung Cancer and Precision Medicine

4. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

5. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and evaluation of a rociletinib analog as prospective imaging double mutation L858R/T790M in non-small cell lung cancer;Journal of Pharmacy & Pharmacognosy Research;2024-03-01

2. Development of a NIR fluorescent probe for fluorescence-assisted EGFR-TKI applicable patients screening and drug resistance monitoring;European Journal of Medicinal Chemistry;2023-12

3. Current Status of Cancer Genomics and Imaging Phenotypes: What Radiologists Need to Know;Radiology: Imaging Cancer;2023-11-01

4. First-in-Humans PET Imaging ofKRAS^G12CMutation Status in Non–Small Cell Lung and Colorectal Cancer Patients Using [¹⁸F]PFPMD;Journal of Nuclear Medicine;2023-10-12

5. Controlled Release of Hydrogen‐Carrying Perfluorocarbons for Ischemia Myocardium‐Targeting ¹⁹F MRI‐Guided Reperfusion Injury Therapy;Advanced Science;2023-08-18